Valuation Fate Therapeutics, Inc. Börse Stuttgart
Stocks
F6T
US31189P1021
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
15:55:21 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 1.984 EUR | -5.16% |
|
-3.68% | +151.38% |
Company Valuation: Fate Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,587 | 980.4 | 368.8 | 187.9 | 113.3 | 293.6 | - | - |
| Change | - | -82.45% | -62.39% | -49.04% | -39.69% | 159% | - | - |
| Enterprise Value (EV) | 4,971 | 544.2 | 53.6 | -118.8 | 113.3 | 293.6 | 293.6 | 293.6 |
| Change | - | -89.05% | -90.15% | -321.66% | 195.41% | 159% | 0% | 0% |
| P/E | -26.1x | -3.47x | -2.28x | -1.01x | -0.85x | -2.19x | -2.31x | -2.16x |
| PBR | 8.25x | 2.03x | 0.98x | 0.59x | - | - | - | - |
| PEG | - | -0.1x | 0.1x | - | 0x | 0.29x | 0.46x | -0.32x |
| Capitalization / Revenue | 100x | 10.2x | 5.8x | 13.8x | 17.1x | 50.3x | 61.6x | 73.2x |
| EV / Revenue | 0x | 0x | 0x | -0x | 0x | 50.3x | 61.6x | 73.2x |
| EV / EBITDA | -0x | -0x | -0x | 0x | -0x | -2.46x | -1.92x | - |
| EV / EBIT | -0x | -0x | -0x | 0x | -0x | -2.18x | -1.94x | -1.64x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -2.64x | -2.49x | -2.16x |
| FCF Yield | -3.82% | -28.9% | -37.5% | -65.8% | -98.8% | -37.8% | -40.2% | -46.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | -1.063 | -1.01 | -1.078 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 55.85 | 96.3 | 63.53 | 13.63 | 6.646 | 5.838 | 4.767 | 4.008 |
| EBITDA 1 | -211.1 | -294.6 | -172.2 | -191.3 | -134.8 | -119.3 | -153.1 | - |
| EBIT 1 | -217 | -308.4 | -190.5 | -210.3 | -147.7 | -134.7 | -151.5 | -178.9 |
| Net income 1 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -128.2 | -142.3 | -172.5 |
| Net Debt | -615.9 | -436.2 | -315.2 | -306.7 | - | - | - | - |
| Reference price 2 | 58.510 | 10.090 | 3.740 | 1.650 | 0.983 | 2.330 | 2.330 | 2.330 |
| Nbr of stocks (in thousands) | 95,494 | 97,170 | 98,602 | 113,894 | 115,352 | 119,821 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 3/5/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.11x | 7.75x | 15.8x | 1.34% | 73.96B | |
| 36.85x | 9.53x | 29.23x | 0.04% | 64.66B | |
| -79.06x | 14.77x | -71.24x | -.--% | 27.32B | |
| -17.19x | 6.91x | -8.97x | -.--% | 27.86B | |
| 32.87x | 6.47x | 17.14x | -.--% | 25.97B | |
| 27.08x | 5.08x | 17.06x | -.--% | 19.98B | |
| 51.97x | 19.21x | 38.91x | 0.29% | 17.84B | |
| -1000000x | 41.19x | -1441.61x | -.--% | 16.24B | |
| 16.61x | 4.92x | 11.49x | -.--% | 13.3B | |
| Average | -111,100.97x | 12.87x | -154.69x | 0.19% | 31.9B | |
| Weighted average by Cap. | -56,560.79x | 10.91x | -72.87x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- FATE Stock
- F6T Stock
- Valuation Fate Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
